Author(s): Frenzel T, Lee CZ, Kim H, Quinnine NJ, Hashimoto T,
Abstract Share this page
Abstract BACKGROUND: Tetracyclines may be useful in preventing pathological vascular remodeling, thus decreasing the risk of spontaneous hemorrhage from brain vascular malformations. METHODS: Arteriovenous malformation (AVM) and intracranial aneurysm patients undergoing noninvasive management were treated with minocycline or doxycycline (200 mg/day) up to 2 years in a prospective open-label safety pilot trial. The primary outcome was to compare dose-limiting intolerance, defined as treatment-related dose reduction or withdrawal between the agents. RESULTS: Twenty-six patients with AVMs (n = 12) or aneurysms (n = 14) were recruited. Adverse event rates were similar to other reported trials of these agents; 4 of 13 (31\%) minocycline and 3 of 13 (23\%) doxycycline patients had dose-limiting intolerance (hazard ratio = 3.1, 95\% CI = 0.52-18.11, log rank p = 0.70). CONCLUSIONS: It is feasible to propose a long-term trial to assess the potential benefit of tetracycline therapy to decrease hemorrhagic risk in brain vascular malformations. (c) 2008 S. Karger AG, Basel.
This article was published in Cerebrovasc Dis
and referenced in Surgery: Current Research